Tech Update: SAPIEN Aortic Valve Replacement Shines At S.T.S.

By Adam Pick on February 1, 2012

Earlier this week, the 48th annual Society of Thoracic Surgeons Meeting (STS) was held in Fort Lauderdale, Florida. During the meeting, cardiac surgeons from around the world gather to discuss the latest strategies for optimal cardiac treatment — including heart valve repair and heart valve replacement procedures.

As our patient and caregiver community is fascinated by medical advances impacting heart valve surgery, I thought you might be interested to learn about a new study released at STS specific to the SAPIEN transcatheter aortic valve replacement device. The SAPIEN, which is manufactured by Edwards Lifesciences, is positioned in the heart using a minimally invasive catheter.

 

 

Here are the most recent findings about the SAPIEN’s clinical performance in 822 “inoperable patients” who suffered from severe aortic valve stenosis and received this aortic valve replacement device transapically — through the ribs:

  • The average predicted risk of operative mortality at 30 days, according to the STS Adult Cardiac Database, was 12.2 percent. During this SAPIEN study, mortality at 30 days was 8.2 percent.
  • Mortality after one year was 23.6 percent, a significant decrease from 29.1 percent in an earlier SAPIEN study.
  • The stroke rate, one month after SAPIEN implant, was 2 percent — compared with 7 percent in the initial study and 5.5 percent of those getting traditional surgery.

In a statement, Mike Mussallem, the CEO of Edwards Lifesciences noted, “We believe this more recent experience adds strong new support to the transapical procedure as an important option for patients who are at high-risk for surgery.”

To see how the SAPIEN aortic valve replacement is implanted, here is a fascinating animation which shows the transapical approach.

 

 

If you didn’t know, the SAPIEN received FDA-approval for inoperable patients last November. Edwards is now waiting for FDA approval of the device for patients at “high-risk” from standard surgery.

Keep on tickin!
Adam


Written by Adam Pick
- Patient & Website Founder

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded HeartValveSurgery.com to educate and empower patients. This award-winning website has helped over 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and Medical News Today.

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded HeartValveSurgery.com to educate and empower patients. This award-winning website has helped over 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and Medical News Today.


Grace Jacobs says on February 2nd, 2012 at 9:37 am

I found the comments about the Sapien implant very interesting and plan to let my cardiologist know of this in case he wasn’t aware of it.

I had replacement of my aortic valve 9 years ago – I have a St. Jude Mechanical Valve and am doing well. The only draw back and I wish something will be discovered before long is the matter of having my blood tested every 3 to 4 weeks due to my taking Coumadin for life. Other than that, I do everything I always did. I am in my 70’s now.

Would love to hear about anyone else who experiences taking Coumadin and their thoughts.

Thank you. As always, Adma, I appreciate your up-to-date information. It is always informative and helpful.

Grace


Leave a Reply

Adam's Newest Blogs

Adam's Newest Posts

One Thumb-Up, A Red Pillow & 9,500 Facebook Likes for John! Learn More.

Low-Risk TAVR Clinical Trial Results Released Learn More.

Newest Community Post

Claire says, "Big day of testing today. I had the MRI"
Read more

Selene says, "Hi. I am 56 years old. I have been"
Read more

Marc says, "Almost a year has passed since OHS for"
Read more

Find Heart Valve Surgeons

Search 1,500 patient-recommended surgeons